Catumaxomab: Clinical development and future directions

Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the european Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites. The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab(®)) together with its partner T...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Linke, Rolf, Klein, Anke, Seimetz, Diane
Format: Artigo
Sprog:Inglês
Udgivet: Landes Bioscience 2010
Fag:
Mini-Reviews
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840231/
https://ncbi.nlm.nih.gov/pubmed/20190561
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker